KalGene Pharmaceuticals
Latest round
- Series A
Last raised
- Nov 2017
Total raised
- Undisclosed
Investors
- 3
About KalGene Pharmaceuticals
KalGene Pharmaceuticals Inc.Founded in 2007 in Candiac, Canada, KalGene Pharmaceuticals Inc. specializes in developing solutions for Alzheimer's patients.KalGene Inc. specializes in developing innovative solutions for Alzheimer's patients, with a focus on their flagship product, KG207. This product aims to enhance cognitive function and slow the progression of Alzheimer’s disease by targeting specific neurochemical pathways. KG207 has been designed following extensive research and clinical trials, addressing critical needs in the healthcare sector for effective Alzheimer’s treatments. The company serves a diverse client base that includes healthcare providers, research institutions, and patients directly affected by Alzheimer's.Kalgene Inc. generates revenue through a multi-faceted transaction structure that includes partnerships with healthcare providers and direct-to-consumer sales. Transactions often involve licensing agreements with hospitals and clinics that utilize KG207 as part of their treatment protocols for patients with Alzheimer's. Additionally, the company engages in collaborations with pharmaceutical distributors, ensuring that their products reach a wider audience. Pricing plans are structured to accommodate both institutional clients and individual consumers, reflecting the value of KG207 as a leading treatment option.KalGene Pharmaceuticals Inc. is focused on launching new products, including advancements to KG207, with the aim of enhancing its efficacy in treating Alzheimer's. The company plans to expand its market reach into Europe and Asia by 2022, targeting regions with a growing elderly population. This includes ongoing research and development efforts that are critical for addressing the evolving needs of Alzheimer's patients.
Who invested in KalGene Pharmaceuticals
3 investors across 1 round
See all investors in KalGene Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 15, 2017
Amount
Undisclosed
Investors
Questions about KalGene Pharmaceuticals
Who invested in KalGene Pharmaceuticals?
KalGene Pharmaceuticals has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has KalGene Pharmaceuticals raised?
KalGene Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did KalGene Pharmaceuticals last raise money?
KalGene Pharmaceuticals's most recent round on record is a Series A, in Nov 2017.
What does KalGene Pharmaceuticals do?
KalGene Pharmaceuticals is a pharmaceuticals company.
Where is KalGene Pharmaceuticals headquartered?
KalGene Pharmaceuticals is headquartered in Candiac, Canada.
Which VCs invest in companies like KalGene Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at KalGene Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like KalGene Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.